Ontak gains full US approval for CD25-positive cutaneous T-cell lymphoma
This article was originally published in Scrip
Executive Summary
Eisaihas received full US FDAapproval for its fusion protein Ontak (denileukin diftitox) for the orphan indication of persistent or recurrent CD25-positive cutaneous T-cell lymphoma (CTCL), following a Phase III trial which confirmed response rate benefits in such patients.
You may also be interested in...
Quick Listen: Scrip’s Five Must-Know Things
Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.
Japan Regulators Kept On Track Despite Pandemic
While it was not as affected as some other countries, Japan still had the pandemic to deal with and regulators responded while managing to keep up regular product review work, including several world-first approvals. Coronavirus vaccine roll-outs and the first general annual reimbursement price cut are on the cards for this year.
Quick Listen: Scrip’s Five Must-Know Things
Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.
Need a specific report? 1000+ reports available
Buy Reports